PMID- 28979818
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2156-6976 (Print)
IS  - 2156-6976 (Electronic)
IS  - 2156-6976 (Linking)
VI  - 7
IP  - 9
DP  - 2017
TI  - Erlotinib in combination with bevacizumab and FOLFOX4 as second-line chemotherapy 
      for patients with metastatic colorectal cancer.
PG  - 1971-1977
AB  - BACKGROUND: We conducted a phase II study by combining FOLFOX4 plus bevacizumab 
      (BV) with erlotinib (ER) as second-line chemotherapy for patients with metastatic 
      colorectal cancer (mCRC). METHODS: Patients were divided into two groups in 
      randomized double-blind manner. One group was given FOLFOX4 plus 5 mg/kg BV on 
      day 1 of 2-week cycle. The other group was given 2-week-cycle of BV + FOLFOX4, 
      and 100 mg ER every day. The primary endpoint was progression-free survival 
      (PFS). The secondary endpoints were overall survival (OS), clinical response 
      rates and adverse events (AEs). RESULTS: 66 patients received 2nd-line treatment 
      of ER + BV+ FOLFOX4, and 65 received BV + FOLFOX4. Median PFS was 9.6 months of 
      ER + BV + FOLFOX4 group, significantly better than 6.9 months of BV + FOLFOX4 
      group (P = 0.021, HR = 1.15, 95% CI = 0.88-1.39). Medium OS for ER + BV + FOLFOX4 
      group was 12.5 months, not statistically different than 12.1 months for BV + 
      FOLFOX4 group (P = 00.146, HR = 0.63, 95% CI = 0.34-1.02). Combined partial 
      response and stable disease rate was 48.5% for ER + BV + FOLFOX4 group, 
      significantly higher than 32.2% for BV + FOLFOX4 group (P = 0.015). Patients in 
      ER + BV + FOLFOX4 group had higher incidence rates of AEs. CONCLUSION: In 
      second-line chemotherapy for patients with mCRC, combining erlotinib with FOLFOX4 
      plus bevacizumab may improve PFS, clinical response rates, but not OS. AEs, 
      though with high incidence rates, were generally tolerable among patients 
      receiving multiple reagents.
FAU - Shi, Sha
AU  - Shi S
AD  - Department of Gastroenterology, Liaocheng People's HospitalLiaocheng 252000, 
      China.
FAU - Lu, Kemei
AU  - Lu K
AD  - Department of Gastroenterology, Liaocheng People's HospitalLiaocheng 252000, 
      China.
FAU - Gao, Hui
AU  - Gao H
AD  - Department of Gastroenterology, Liaocheng People's HospitalLiaocheng 252000, 
      China.
FAU - Sun, Huidong
AU  - Sun H
AD  - Department of General Surgery, Liaocheng People's HospitalLiaocheng 252000, 
      China.
FAU - Li, Senlin
AU  - Li S
AD  - Department of General Surgery, Liaocheng People's HospitalLiaocheng 252000, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20170901
PL  - United States
TA  - Am J Cancer Res
JT  - American journal of cancer research
JID - 101549944
PMC - PMC5622230
OTO - NOTNLM
OT  - FOLFOX4
OT  - Metastatic colorectal cancer
OT  - bevacizumab
OT  - erlotinib
OT  - second-line chemotherapy
COIS- None.
EDAT- 2017/10/06 06:00
MHDA- 2017/10/06 06:01
PMCR- 2017/09/01
CRDT- 2017/10/06 06:00
PHST- 2016/08/31 00:00 [received]
PHST- 2016/09/25 00:00 [accepted]
PHST- 2017/10/06 06:00 [entrez]
PHST- 2017/10/06 06:00 [pubmed]
PHST- 2017/10/06 06:01 [medline]
PHST- 2017/09/01 00:00 [pmc-release]
PST - epublish
SO  - Am J Cancer Res. 2017 Sep 1;7(9):1971-1977. eCollection 2017.